References
- Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201.
- Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-Severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
- Sands BE, Marano C. Ustekinumab as induction and maintenance therapy for ulcerative colitis. Reply. N Engl J Med. 2020;382(1):91.
- Jairath V, Khanna R, Zou GY, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42(10):1200–1210.
- Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–1666.
- Reinisch W, Gottlieb K, Colombel JF, et al. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development. Clin Gastroenterol Hepatol. 2019;17(9):1673–1679.e1.
- Ma C, Sandborn WJ, D'Haens GR, et al. Discordance between Patient-Reported outcomes and mucosal inflammation in patients with mild to moderate ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(8):1760–1768.e1.
- Narula N, Alshahrani AA, Yuan Y, et al. Patient-Reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and Meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice journal of the. Clin Gastroenterol Hepatol. 2019;17(3):411–418.e3.
- Dulai PS, Singh S, Jairath V, et al. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(4):435–445.
- Colombel JF, Keir ME, Scherl A, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66(12):2063–2068.
- Jharap B, Sandborn WJ, Reinisch W, et al. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42(9):1082–1092.
- Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45(6):801–813.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.
- Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review. Dig Liver Dis. 2021;53(7):803–808.
- Pinto S, Loddo E, Paba S, et al. Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic. J Patient Rep Outcomes. 2021;5(1):48.
- Peyrin-Biroulet L, Van Assche G, Armuzzi A, et al. Implementing the concept of continuous clinical response into clinical practice for ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15(8):1154–1161.e1.
- Del Hoyo J, Nos P, Faubel R, et al. A Web-Based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: Pilot randomized controlled trial. J Med Internet Res. 2018;20(11):e11602.
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
- Administration USFaD. Ulcerative Colitis: Developing Drugs for Treatment Guidance for Industry. [Draft Guidance]. In press 2022.
- Restellini S, Chao CY, Martel M, et al. Clinical parameters correlate with endoscopic activity of ulcerative colitis: a systematic review. Clinical gastroenterology and hepatology: the official clinical practice journal of the. Clin Gastroenterol Hepatol. 2019;17(7):1265–1275.e8.
- Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1246–1256.e6.
- Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of crohn's disease activity. Aliment Pharmacol Ther. 2015;41(1):77–86.
- Peyrin-Biroulet L, Reinisch W, Colombel J-F, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in crohn's disease in the SONIC trial. Gut. 2014;63(1):88–95.
- Jones J, Loftus EV, Jr Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with crohn's disease. Clinical Gastroenterology and Hepatology. 2008;6(11):1218–1224.
- Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic crohn's disease. A prospective multicentre study of 121 cases. The groupe d'Etudes therapeutiques des affections inflammatoires digestives. Gut. 1994;35(2):231–235.